http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014114617-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5748 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate | 2012-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014114617-A |
| titleOfInvention | COMBINED TREATMENTS CONTAINING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS |
| abstract | 1. A method of treating a patient with a malignant tumor, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. A method of treating a patient with a malignant tumor, which is characterized by an increased likelihood of developing resistance to a B-raf antagonist, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. 3. A method of increasing and / or restoring sensitivity to a B-raf antagonist, comprising administering to a cancer patient an effective amount of a B-raf antagonist and a c-met antagonist. 4. A method of increasing the sensitivity period to a B-raf antagonist, comprising administering to a patient with a malignant tumor an effective amount of a B-raf antagonist and a c-met antagonist. A method of treating a patient with a B-raf antagonist resistant malignant tumor, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. A method for increasing the duration of a response to a B-raf antagonist, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. A method for slowing down or preventing a patient from developing a malignant tumor with HGF-mediated resistance to a B-raf antagonist, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. The method of claim 7, wherein the patient's malignant tumor has been shown to express a B-raf biomarker. The method of claim 8, wherein the B-raf biomarker is B-raf V600.10. The method of claim 8, wherein the B-raf biomarker is a B-raf V600E.11. The method according to any one of paragraphs. 8-10, in which the expression of the biomarker of mutant B-raf in malignancy |
| priorityDate | 2011-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.